Harmonizing Optimal Strategy for Treatment of Coronary Atherosclerotic Lesions - Registry-based Study on the Effect and Safety of Onyx™, Zotarolimus-eluting Stent for Coronary Atherosclerotic Lesions: HOST-Onyx Registry
Latest Information Update: 05 May 2021
Price :
$35 *
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary arteriosclerosis; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms HOST-ONYX
- 02 Nov 2017 Results of pooled data from two prospective registries of patients who received Resolute Onyx and Resolute Integrity (HOST-ONYX and HOST-RESOLINTE Registries), were presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
- 16 May 2017 New trial record